AU
UK
CA
NZ
IND
US
Last update at 2026-06-05T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors
Thu 08 May 25, 09:00 AM| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -21.22302M | -15.60107M | -7.26398M | -12.24478M | -4.89179M |
| Minority interest | - | - | - | - | - |
| Net income | -21.22611M | -14.88079M | -7.98784M | -14.67761M | -4.87031M |
| Selling general administrative | 11.45M | 8.89M | 7.83M | 4.85M | 2.31M |
| Selling and marketing expenses | - | 8876.87M | - | - | - |
| Gross profit | 7.92M | -8.31159M | 0.50M | - | - |
| Reconciled depreciation | 0.03M | 0.03M | 0.03M | 0.03M | 0.02M |
| Ebit | -20.26562M | -17.22471M | -7.36016M | -9.81194M | -4.87031M |
| Ebitda | -20.23826M | -17.19735M | -7.33280M | -9.78458M | -4.87566M |
| Depreciation and amortization | 0.03M | 0.03M | 0.03M | 0.03M | -0.00535M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -20.26562M | -17.24971M | -7.90335M | -9.81194M | -4.87031M |
| Other operating expenses | 28.21M | 20.80M | 13.91M | 9.81M | 4.87M |
| Interest expense | - | - | - | 2.43M | 0.02M |
| Tax provision | 0.00309M | -0.72029M | 0.72M | - | - |
| Interest income | - | - | - | - | - |
| Net interest income | - | - | - | - | 0.00000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.00309M | -0.72029M | 0.72M | 2.43M | -0.02148M |
| Total revenue | 7.95M | 3.55M | 6.00M | 0.00000M | 0.00000M |
| Total operating expenses | 28.18M | 8.94M | 8.40M | 9.81M | 4.87M |
| Cost of revenue | 0.03M | 11.87M | 5.50M | - | - |
| Total other income expense net | -0.95739M | 1.65M | 0.64M | -2.43284M | -0.02148M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -21.22611M | -14.88079M | -12.36148M | -12.24478M | -4.89179M |
| Net income applicable to common shares | - | - | - | -12.24478M | -4.89179M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 49.95M | 44.35M | 41.27M | 8.40M | 4.79M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 3.12M | 5.24M | 1.07M | 1.25M | 0.24M |
| Total liab | 6.92M | 4.77M | 5.63M | 16.79M | 1.15M |
| Total stockholder equity | 43.03M | 39.58M | 35.65M | -8.39354M | 3.64M |
| Deferred long term liab | - | - | - | 1.12M | 0.09M |
| Other current liab | 3.61M | 1.39M | 2.25M | 2.01M | 0.29M |
| Common stock | 0.00209M | 0.00167M | 0.00144M | 0.00026M | 0.00026M |
| Capital stock | 0.00209M | 0.00167M | 0.00144M | 8.79M | 8.79M |
| Retained earnings | -61.96328M | -40.73717M | -25.85638M | -17.86855M | -5.62377M |
| Other liab | - | - | - | - | - |
| Good will | - | - | - | - | - |
| Other assets | - | -44264.11957M | - | 1.12M | 0.09M |
| Cash | 46.82M | 38.34M | 32.63M | 5.93M | 4.34M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 5.87M | 3.82M | 5.05M | 3.82M | 1.15M |
| Current deferred revenue | 1.20M | 0.85M | 0.92M | - | - |
| Net debt | -46.82279M | -38.33976M | -32.62677M | 7.03M | -4.34018M |
| Short term debt | - | - | 0.72M | - | - |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | - | - | - | 12.97M | - |
| Other stockholder equity | 104.99M | 80.31M | 61.50M | 0.68M | 0.47M |
| Property plant equipment | - | - | - | 0.09M | 0.12M |
| Total current assets | 49.94M | 44.31M | 41.20M | 7.18M | 4.58M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | - | -17.18718M | -5.14991M |
| Short term investments | - | 38301.42M | - | - | - |
| Net receivables | - | 0.73M | 7.50M | - | - |
| Long term debt | - | - | - | 12.97M | - |
| Inventory | - | - | - | - | - |
| Accounts payable | 1.06M | 1.59M | 1.16M | 1.82M | 0.86M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | -0.01125M | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | - | 38.55M | - | 1.12M | 0.09M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 0.01M | 0.04M | 0.08M | 1.21M | 0.21M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.02500M | -0.74000M | -0.52500M | -0.13680M |
| Change to liabilities | - | - | - | 0.85M | 0.67M |
| Total cashflows from investing activities | -1.16460M | -0.02500M | -0.54319M | -0.52500M | -0.13680M |
| Net borrowings | - | - | 0.00000M | 10.47M | 10.47M |
| Total cash from financing activities | 20.39M | 16.03M | 38.43M | 9.36M | -0.34058M |
| Change to operating activities | - | - | - | -0.09345M | 0.07M |
| Net income | -21.22611M | -14.88079M | -7.98784M | -12.24478M | -4.89179M |
| Change in cash | 8.48M | 5.71M | 26.69M | 1.59M | -4.38066M |
| Begin period cash flow | 38.34M | 32.63M | 5.93M | 4.34M | 8.72M |
| End period cash flow | 46.82M | 38.34M | 32.63M | 5.93M | 4.34M |
| Total cash from operating activities | -10.73930M | -10.28882M | -11.18881M | -7.23935M | -3.90327M |
| Issuance of capital stock | 20.35M | 14.00M | 38.34M | - | 0.00000M |
| Depreciation | 0.03M | 0.03M | 0.03M | 0.03M | 0.02M |
| Other cashflows from investing activities | -1.16460M | -0.02500M | -0.54319M | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | - | 7.50M | -7.50000M | - | - |
| Sale purchase of stock | - | - | - | - | - |
| Other cashflows from financing activities | 20.39M | 2.02M | 0.09M | 9.36M | -0.34058M |
| Change to netincome | - | - | - | 3.23M | 0.23M |
| Capital expenditures | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.14M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 3.88M | 1.88M | -4.64377M | 0.75M | 0.74M |
| Stock based compensation | 4.29M | 2.66M | 0.87M | 0.21M | 0.23M |
| Other non cash items | 2.29M | 0.03M | 0.54M | 4.02M | - |
| Free cash flow | -10.73930M | -10.28882M | -11.18881M | -7.23935M | -4.04007M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| COYA Coya Therapeutics, Inc. Common Stock |
-0.45 9.24% | 4.42 | - | - | 13.37 | 2.72 | 8.85 | -6.2093 |
| NVO Novo Nordisk A/S |
-0.79 1.81% | 42.96 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-0.6937 1.57% | 43.50 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
5.09 1.15% | 446.83 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
6.72 1.07% | 635.45 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, its pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.
5850 San Felipe St., Houston, TX, United States, 77057
| Name | Title | Year Born |
|---|---|---|
| Dr. Howard Berman Ph.D. | Chairman & CEO | 1974 |
| Dr. Fred Grossman D.O., FAPA | President & Chief Medical Officer | 1962 |
| Mr. David S. Snyder | CFO & COO | 1960 |
| Dr. Gregory MacMichael Ph.D. | Chief Technical Officer | 1956 |
| Dr. Michelle Frazier Ph.D. | Senior Vice President of Regulatory Affairs | NA |
| Mr. Aaron Thome Ph.D. | Head of Neuroinflammation Platform | NA |
| Dr. Arun Swaminathan Ph.D. | Chief Business Development Officer | NA |
| Dr. Arun Swaminathan Ph.D. | CEO & Director | 1970 |
| Dr. Fred Grossman D.O., FAPA | President & Chief Medical Officer | 1959 |
| Mr. David S. Snyder M.B.A. | CFO & COO | 1960 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...